Patents by Inventor Elizabeth I. Parkinson
Elizabeth I. Parkinson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240101995Abstract: The present disclosure teaches a method of treating a patient in need of therapeutic intervention with bioactive cyclic peptide molecules which are useful as antimicrobials, anticancer agents, antiparasitic, immunosuppressants, and others.Type: ApplicationFiled: November 30, 2023Publication date: March 28, 2024Applicant: Purdue Research FoundationInventors: Elizabeth I. Parkinson, Matthew A. Hostetler
-
Patent number: 11879142Abstract: The present disclosure reaches a method of a unique combination of bioinformatic technical tools together with chemical synthesis for identification of bioactive peptide molecules based on non-ribosomal peptide synthetases. Those bioactive cyclic peptide molecules are useful as antimicrobials, anticancer agents, antiparasitic, immunosuppressants, and others. Series of useful cyclic peptides and the pharmaceutical compositions thereof are within the scope of this disclosure.Type: GrantFiled: February 24, 2022Date of Patent: January 23, 2024Assignee: Purdue Research FoundationInventors: Elizabeth I. Parkinson, Matthew A. Hostetler
-
Publication number: 20220282238Abstract: The present disclosure reaches a method of a unique combination of bioinformatic technical tools together with chemical synthesis for identification of bioactive peptide molecules based on non-ribosomal peptide synthetases. Those bioactive cyclic peptide molecules are useful as antimicrobials, anticancer agents, antiparasitic, immunosuppressants, and others. Series of useful cyclic peptides and the pharmaceutical compositions thereof are within the scope of this disclosure.Type: ApplicationFiled: February 24, 2022Publication date: September 8, 2022Applicant: Purdue Research FoundationInventors: Elizabeth I. Parkinson, Matthew A. Hostetler
-
Patent number: 10576096Abstract: The therapies described herein can be selectively lethal toward a variety of different cancer cell types and cancer conditions in a subject. The combination therapies described herein can be useful for the management, treatment, control, or adjunct treatment of diseases, where the selective legality is beneficial in chemotherapeutic therapy, particularly where the disease is accompanied by elevated levels of NQO1.Type: GrantFiled: December 6, 2017Date of Patent: March 3, 2020Assignees: The Board of Regents of the University of Texas System, The Board of Trustees of the University of IllinoisInventors: Paul J. Hergenrother, David A. Boothman, Joseph S. Bair, Lifen Cao, Jinming Gao, Xiumei Huang, Xiuquan Luo, Xinpeng Ma, Zachary R. Moore, Elizabeth I. Parkinson
-
Patent number: 10285986Abstract: Compositions comprising Formula (I) can be selectively lethal toward a variety of different cancer cell types. The compositions are useful for the management, treatment, control, or adjunct treatment of diseases, where the selective lethality is beneficial in chemotherapeutic therapy.Type: GrantFiled: March 23, 2018Date of Patent: May 14, 2019Assignees: The Board of Trustees of the University of Illinois, The Board of Regents of the University of Texas SystemInventors: Paul J. Hergenrother, David A. Boothman, Joseph S. Bair, Rahul Palchaudhuri, Elizabeth I. Parkinson
-
Patent number: 10272099Abstract: The therapies described herein can be selectively lethal toward a variety of different cancer cell types and cancer conditions in a subject. The combination therapies described herein can be useful for the management, treatment, control, or adjunct treatment of diseases, where the selective lethality is beneficial in chemotherapeutic therapy, particularly where the disease is accompanied by elevated levels of NQO1.Type: GrantFiled: April 8, 2014Date of Patent: April 30, 2019Assignees: The Board of Regents of the University of Texas System, The Board of Trustees of the University of Illinois.Inventors: Paul J. Hergenrother, David A. Boothman, Joseph S. Bair, Lifen Cao, Jinming Gao, Xiumei Huang, Xiuquan Luo, Xinpeng Ma, Zachary R. Moore, Elizabeth I. Parkinson
-
Publication number: 20180207150Abstract: Compositions comprising Formula (I) can be selectively lethal toward a variety of different cancer cell types. The compositions are useful for the management, treatment, control, or adjunct treatment of diseases, where the selective lethality is beneficial in chemotherapeutic therapy.Type: ApplicationFiled: March 23, 2018Publication date: July 26, 2018Applicants: The Board of Trustees of the University of Illinois, The Board of Regents of the University of Texas SystemInventors: Paul J. HERGENROTHER, David A. BOOTHMAN, Joseph S. BAIR, Rahul PALCHAUDHURI, Elizabeth I. PARKINSON
-
Publication number: 20180099002Abstract: The therapies described herein can be selectively lethal toward a variety of different cancer cell types and cancer conditions in a subject. The combination therapies described herein can be useful for the management, treatment, control, or adjunct treatment of diseases, where the selective legality is beneficial in chemotherapeutic therapy, particularly where the disease is accompanied by elevated levels of NQO1.Type: ApplicationFiled: December 6, 2017Publication date: April 12, 2018Applicants: The Board of Regents of the University of Texas System, The Board of Trustees of the University of IllinoisInventors: Paul J. HERGENROTHER, David A. BOOTHMAN, Joseph S. BAIR, Lifen CAO, Jinming GAO, Xiumei HUANG, Xiuquan LUO, Xinpeng MA, Zachary R. MOORE, Elizabeth I. PARKINSON
-
Patent number: 9925180Abstract: Compositions comprising Formula (I) can be selectively lethal toward a variety of different cancer cell types. The compositions are useful for the management, treatment, control, or adjunct treatment of diseases, where the selective lethality is beneficial in chemotherapeutic therapy.Type: GrantFiled: March 9, 2017Date of Patent: March 27, 2018Assignees: The Board of Trustees of the University of Illinois, The Board of Regents of the University of Texas SystemInventors: Paul J. Hergenrother, David A. Boothman, Joseph S. Bair, Rahul Palchaudhuri, Elizabeth I. Parkinson
-
Patent number: 9920069Abstract: Compounds that specifically kill fluoroquinolone (FQ) resistant bacteria have been developed and are described herein. The FQs are the most commonly prescribed antibiotics to adults in the U.S. and thus are extremely important drugs. However, bacterial resistant to these drugs is now ubiquitous in some of the most common and deadly Gram-positive pathogens, including methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci (VRE). Indeed, FQs are no longer indicated for treatment of MRSA and VRE infections because of such resistance. The compounds have specific and potent activity versus MRSA and VRE.Type: GrantFiled: March 17, 2015Date of Patent: March 20, 2018Assignee: The Board of Trustees of the University of IllinoisInventors: Paul J. Hergenrother, Elizabeth I. Parkinson, Joseph S. Bair
-
Publication number: 20170182030Abstract: Compositions comprising Formula (I) can be selectively lethal toward a variety of different cancer cell types. The compositions are useful for the management, treatment, control, or adjunct treatment of diseases, where the selective lethality is beneficial in chemotherapeutic therapy.Type: ApplicationFiled: March 9, 2017Publication date: June 29, 2017Applicants: The Board of Trustees of the University of Illinois, The Board of Regents of the University of Texas SystemInventors: Paul J. HERGENROTHER, David A. Boothman, Joseph S. Bair, Rahul Palchaudhuri, Elizabeth I. Parkinson
-
Publication number: 20170096436Abstract: Compounds that specifically kill fluoroquinolone (FQ) resistant bacteria have been developed and are described herein. The FQs are the most commonly prescribed antibiotics to adults in the U.S. and thus are extremely important drugs. However, bacterial resistant to these drugs is now ubiquitous in some of the most common and deadly Gram-positive pathogens, including methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci (VRE). Indeed, FQs are no longer indicated for treatment of MRSA and VRE infections because of such resistance. The compounds have specific and potent activity versus MRSA and VRE.Type: ApplicationFiled: March 17, 2015Publication date: April 6, 2017Applicant: The Board of Trustees of the University of IIIinoisInventors: Paul J. HERGENROTHER, Elizabeth I. PARKINSON, Joseph S. BAIR
-
Patent number: 9611266Abstract: Compounds of Formula (I) can be selectively lethal toward a variety of different cancer cell types. The compounds are useful for the management, treatment, control, or adjunct treatment of diseases, where the selective lethality is beneficial in chemotherapeutic therapy.Type: GrantFiled: January 11, 2016Date of Patent: April 4, 2017Assignees: The Board of Trustees of the University of Illinois, The Board of Regents of the University of Texas SystemInventors: Paul J. Hergenrother, David A. Boothman, Joseph S. Bair, Rahul Palchaudhuri, Elizabeth I. Parkinson
-
Publication number: 20160122348Abstract: Compounds of Formula (I) can be selectively lethal toward a variety of different cancer cell types. The compounds are useful for the management, treatment, control or adjunct treatment of diseases, where the selective lethality is beneficial in chemotherapeutic therapy.Type: ApplicationFiled: January 11, 2016Publication date: May 5, 2016Applicants: The Board of Trustees of the University of Illinois, The Board of Regents of the University of Texas SystemInventors: Paul J. Hergenrother, David A. Boothman, Joseph S. Bair, Rahul Palchaudhuri, Elizabeth I. Parkinson
-
Publication number: 20160030457Abstract: The therapies described herein can be selectively lethal toward a variety of different cancer cell types and cancer conditions in a subject. The combination therapies described herein can be useful for the management, treatment, control, or adjunct treatment of diseases, where the selective lethality is beneficial in chemotherapeutic therapy, particularly where the disease is accompanied by elevated levels of NQO1.Type: ApplicationFiled: April 8, 2014Publication date: February 4, 2016Applicants: The Board of Regents of the University of Texas System, The Board of Trustees of University of IllinoisInventors: Paul J. HERGENROTHER, David A. BOOTHMAN, Joseph S. BAIR, Lifen CAO, Jinming GAO, Xiumei HUANG, Xiuquan LUO, Xinpeng MA, Zachary R. MOORE, Elizabeth I. PARKINSON
-
Patent number: 9233960Abstract: Compounds of Formula (I) can be selectively lethal toward a variety of different cancer cell types. The compounds are useful for the management, treatment, control, or adjunct treatment of diseases, where the selective lethality is beneficial in chemotherapeutic therapy.Type: GrantFiled: October 12, 2012Date of Patent: January 12, 2016Assignee: The Board of Trustees of the University of IllinoisInventors: Paul J. Hergenrother, David A. Boothman, Joseph S. Bair, Rahul Palchaudhuri, Elizabeth I. Parkinson
-
Publication number: 20150011509Abstract: Compounds of Formula (I) can be selectively lethal toward a variety of different cancer cell types. The compounds are useful for the management, treatment, control, or adjunct treatment of diseases, where the selective lethality is beneficial in chemotherapeutic therapy.Type: ApplicationFiled: October 12, 2012Publication date: January 8, 2015Applicants: The Board of Trustees of the University of Illnois, The Board of Regents of the University of Texas SystemInventors: Paul J. Hergenrother, David A. Boothman, Joseph S. Bair, Rahul Palchaudhuri, Elizabeth I. Parkinson